Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Recommended
'Dueling Dinosaurs:' One-of-a-kind dig at Raleigh science museum opens this weekend
Recommended
Homeowners insurance doesn't cover floods: How to protect your home in North Carolina
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
75.17
+0.14 (+0.19%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6,687,977
Open
75.00
Bid (Size)
75.17 (4)
Ask (Size)
75.55 (2)
Prev. Close
75.03
Today's Range
74.59 - 75.49
52wk Range
60.47 - 75.81
Shares Outstanding
N/A
Dividend Yield
1.24%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Today 11:34 EDT
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
Via
Investor's Business Daily
Top 4 Health Care Stocks That May Plunge This Month
Today 8:09 EDT
Via
Benzinga
Performance
YTD
+9.90%
+9.90%
1 Month
+13.33%
+13.33%
3 Month
+12.16%
+12.16%
6 Month
+18.55%
+18.55%
1 Year
+2.06%
+2.06%
More News
Read More
AstraZeneca Plc (AZN) Q1 2024 Earnings Call Transcript
April 25, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Sanofi Reports Strong Earnings, Joins Kirby, Sonic Automotive, Union Pacific And Other Big Stocks Moving Higher On Thursday
April 25, 2024
Via
Benzinga
Should Quality-Oriented Investors Explore ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN)?
April 23, 2024
Via
Chartmill
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 25, 2024
Via
Benzinga
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
April 25, 2024
Via
Benzinga
Looking At AstraZeneca's Recent Unusual Options Activity
April 19, 2024
Via
Benzinga
Stocks Drop, Tech Tumbles With Meta's Weak Outlook, Q1 Stagflation Fears; Gold Miners Advance: What's Driving Markets Thursday?
April 25, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
April 25, 2024
Via
Investor's Business Daily
AZN Stock Earnings: AstraZeneca Misses EPS, Beats Revenue for Q1 2024
April 25, 2024
Via
InvestorPlace
AstraZeneca, Sanofi Jump On First-Quarter Earnings; Bristol Myers Lags
April 25, 2024
Via
Investor's Business Daily
US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
April 25, 2024
Via
Benzinga
Q1 2024 results
April 25, 2024
From
AstraZeneca
Via
Business Wire
3 Underappreciated Pharmaceutical Stocks to Buy Before They Surge
April 23, 2024
Via
InvestorPlace
European Stock: AstraZeneca
April 22, 2024
Via
Talk Markets
Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges
April 19, 2024
Via
Benzinga
Topics
Brexit
Exposures
Brexit
3 Blue-Chip Stocks to Buy as High Inflation Persists
April 19, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
April 17, 2024
Via
Benzinga
AstraZeneca's Imfinzi/Chemo Combo Doubles Overall Survival In Biliary Tract Cancer Patients At 3 Years, Data Shows
April 16, 2024
Via
Benzinga
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
April 16, 2024
From
AstraZeneca
Via
Business Wire
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
Via
InvestorPlace
Topics
Economy
Exposures
Economy
4 Exceptional Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
April 14, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.